Compare TIPT & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIPT | IRWD |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.8M | 526.7M |
| IPO Year | 2017 | 2009 |
| Metric | TIPT | IRWD |
|---|---|---|
| Price | $17.22 | $4.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 208.3K | ★ 1.9M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | ★ 0.76 | 0.15 |
| Revenue | $488,000.00 | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ $22.67 | $29.13 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $15.49 | $0.55 |
| 52 Week High | $27.38 | $5.78 |
| Indicator | TIPT | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 67.79 |
| Support Level | $17.15 | $3.07 |
| Resistance Level | $18.15 | $5.67 |
| Average True Range (ATR) | 0.32 | 0.23 |
| MACD | 0.09 | 0.12 |
| Stochastic Oscillator | 79.59 | 98.94 |
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.